Back To: Home : Featured Technology : Stem Cell

CLICK HERE FOR WHAT'S NEW IN:
 

Stem Cell Innovations in compound validation deal with Lundbeck
June 2007
SHARING OPTIONS:

VALBY, Denmark—Stem Cell Innovations Inc.  recently announced that it entered an agreement to examine hepatic metabolism of a set of H. Lundbeck A/S compounds using its proprietary C3A human liver cell   line. Lundbeck is a research-based pharmaceutical company, engaged in research to find new drugs for treatment of CNS disorders.
 
"This new collaboration shows the expanding acceptance of our C3A cell line as an excellent platform to study human liver function," says Stem Cell Innovations' CEO Dr. James Kelly. "Our protected C3A cell system has intact human liver machinery, is robust and thoroughly quality controlled, all the prerequisites for larger scale in vitro efficacy and safety programs."
 
C3A is SCI's patented human liver cell line, originally developed for use in an artificial liver used to support patients waiting for transplantation. The cells exhibit a wide variety of human liver functions and are ideal for use in examining the effects of new drugs on the human liver.

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.